

India, Brazil explore new opportunities to expand Pharma trade

The meeting with regulatory officials, and Brazilian healthcare representatives focused on addressing compliance with ANVISA and accelerate responsible market entry for complex therapies such as oncology medicines, biosimilars, and hospital technologies.



New Delhi: Representatives from the government-backed export promotion council, Pharmexcil, convened the India–Brazil Healthcare Business Gateway to facilitate

structured market access to Brazil and streamline regulatory pathways for Indian pharmaceutical exports.

The meeting with regulatory officials, local manufacturers, and Brazilian healthcare representatives focused on addressing compliance with ANVISA and accelerate responsible market entry for complex therapies such as oncology medicines, biosimilars, and hospital technologies.

Brazil, which accounted for around 2.8 per cent (over \$778.49 million) of India’s total pharmaceutical exports in FY25, registering a strong year-on-year (YoY) growth of over 18 per, underscoring its emergence as a steadily expanding market for Indian drugmakers.

During April–January FY26, exports stood at \$740.33 million, significantly higher than \$632.59 million recorded in the year ago period.

“Brazil represents a significant opportunity for Indian MSME pharmaceutical manufacturers, particularly in specialty medicines, public healthcare supply, technology partnerships and regulatory collaboration,” said Namit Joshi, Pharmexcil.

“This meeting represents a strategic step toward supporting initiatives that foster sustainable partnerships and facilitate responsible entry into the Brazilian market,” he added.

News Source:

<https://pharma.economictimes.indiatimes.com/news/pharma-industry/india-brazil-explore-new-opportunities-to-expand-pharma-trade/128781935>